Cancer Treatment—The Champions Advantage

Oct 13 2011 10:29 AM
  • Champions Personalized TumorGrafts™ empower patients and physicians with a diagnostic model that has shown to be predictive of a patient’s clinical response to anticancer therapies. All tested therapies are selected by the Champions team working alongside your physicians.
  • Champions Expert Opinion Panels offer oncology patients and their physicians the opportunity to access a panel of world-leading oncology experts in a unique forum devoted solely to the individual patient.
  • Gene Sequencing identifies the mutations (permanent changes to the DNA) for your individual cancer to help guide your treatment process.

References:

  1. Hidalgo M et al. Activity of gemcitabine in direct patient derived xenografts predicts clinical outcome: validation of an in vivo model for drug development. J Clin Oncol 27:15s, 2009 (suppl; abstr 4528)
  2. Hidalgo M et al. A Pilot Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer. Mol Cancer Ther August 2011 10:1311-1316
  3. Rubio-Viqueira B, Jimeno A, Cusatis G, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res. 2006;12:4652-4661.
  4. Champions data on file.